Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (18229) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Study to Evaluate the Safety and Activity of TTX030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors (TTX-030-002) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (CONNECT) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (SUMMIT)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Treatment Resistance Following AntiCancer Therapies (18150)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CRLA-4 and Anti-PD-1 Blockade in Rare Tumors) (S1609)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial Comparing Paclitaxel, Ifosfamide, and Cisplatin with High-Dose Chemo Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors (A031102) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (DT001) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum (GY019) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (GU006) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (A021703) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial to Assess the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP004)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy (S1418) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (AFT-38) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in combination with Chemotherapy or with Pembrolizumab alone in Patients with Advanced Non- small cell Lung Cancer (MK3475-U01) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members